Document Detail

Can S100B Predict Cerebral Vasospasms in Patients Suffering from Subarachnoid Hemorrhage?
Jump to Full Text
MedLine Citation:
PMID:  23761779     Owner:  NLM     Status:  PubMed-not-MEDLINE    
BACKGROUND: Protein S100B has proven to be a useful biomarker for cerebral damages. Increased levels of serum and cerebrospinal fluid (CSF) S100B have been shown in patients suffering subarachnoid hemorrhage (SAH), severe head injury and stroke. In patients with SAH, the course of S100B levels has been correlated with neurological deficits and outcome. Cerebral vasospasm is a major contributor to morbidity and mortality. The primary aim of this study was to investigate the potential of S100B protein as a predictor of cerebral vasospasm in patients with severe SAH.
MATERIALS AND METHODS: Patients with SAH, Fisher grade 3 and 4, were included in the study. Five samples of CSF and serum S100B were collected from each patient. The first sample (baseline sample) was drawn within the first 3 days following ictus and the following four samples, once a day on days 5-8, with day of ictus defined as day 1. Clinical suspicion of cerebral vasospasm confirmed by computed tomography angiography was used to diagnose cerebral vasospasm.
RESULTS: A total of 18 patients were included. Five patients (28%) developed cerebral vasospasm, two (11%) developed ventriculitis. There were no significant differences between S100B for those with and without vasospasm. Serum S100B levels in patients with vasospasm were slightly lower within the first 5 days following ictus, compared to patients without vasospasm. Two out of five patients had elevated and increasing serum S100B prior to vasospasm. Only one showed a peak level of S100B 1 day before vasospasm could be diagnosed. Due to the low number of patients in the study, statistical significance could not be reached.
CONCLUSION: Neither serum nor CSF S100B can be used as predictor of cerebral vasospasm in patients suffering from SAH.
Moshgan Amiri; Ramona Astrand; Bertil Romner
Related Documents :
25006209 - Clinicoradiological comparison between vascular parkinsonism and parkinson's disease.
23857459 - Comparative study of the safety of regadenoson between patients with mild/moderate chro...
24476129 - Chinese culture permeation in the treatment of parkinson disease: a cross-sectional stu...
24778899 - Impact of iron deficiency anemia on chronic periodontitis and superoxide dismutase acti...
24427569 - Modified stennert's protocol in treating acute peripheral facial nerve paralysis: our e...
23716919 - Oral and salivary changes among renal patients undergoing hemodialysis: a cross-section...
17955279 - Expression of s100b protein levels in serum and cerebrospinal fluid with different form...
24743559 - Viability of pseudomonas aeruginosa in cough aerosols generated by persons with cystic ...
25203949 - The evaluation of qt intervals during diagnosis and after follow-up in acromegaly patie...
Publication Detail:
Type:  Journal Article     Date:  2013-06-06
Journal Detail:
Title:  Frontiers in neurology     Volume:  4     ISSN:  1664-2295     ISO Abbreviation:  Front Neurol     Publication Date:  2013  
Date Detail:
Created Date:  2013-06-13     Completed Date:  2013-06-14     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  101546899     Medline TA:  Front Neurol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  65     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Front Neurol
Journal ID (iso-abbrev): Front Neurol
Journal ID (publisher-id): Front. Neurol.
ISSN: 1664-2295
Publisher: Frontiers Media S.A.
Article Information
Download PDF
Copyright © 2013 Amiri, Astrand and Romner.
Received Day: 22 Month: 2 Year: 2013
Accepted Day: 21 Month: 5 Year: 2013
Electronic publication date: Day: 06 Month: 6 Year: 2013
collection publication date: Year: 2013
Volume: 4E-location ID: 65
PubMed Id: 23761779
ID: 3674401
DOI: 10.3389/fneur.2013.00065

Can S100B Predict Cerebral Vasospasms in Patients Suffering from Subarachnoid Hemorrhage?
Moshgan Amiri12
Ramona Astrand1
Bertil Romner1*
1Department of Neurosurgery, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark
2Faculty of Medicine, Copenhagen University, Copenhagen, Denmark
[edited-by] Edited by: Ronald L. Hayes, Banyan Biomarkers, Inc., USA
[edited-by] Reviewed by: Antonino F. Germano, University of Messina, Italy; Firas H. Kobeissy, University of Florida, USA
Correspondence: *Correspondence: Bertil Romner, Department of Neurosurgery, Blegdamsvej 9, 2100 Copenhagen, Denmark e-mail:
[other] This article was submitted to Frontiers in Neurotrauma, a specialty of Frontiers in Neurology.


Subarachnoid hemorrhage (SAH) accounts for approximately 6–8% of all strokes, and the leading cause is rupture of intracerebral aneurysms in 85% of the cases. The remaining causes are due to arteriovenous malformation (AVM) bleeding, vertebral artery dissection (about 5% together), or due to more undefined causes or the perimesencephalic SAH, which account for about 10% of the cases (van Gijn and Rinkel, 2001). The overall incidence of SAH is approximately 9 per 100,000 persons/year, slightly higher in the Scandinavian countries, an highest in Finland and Japan with 19.7 and 22.7 per 100,000/year, respectively (de Rooij et al., 2007). Mortality and morbidity is high, accounting for up to 50% in patients suffering from aneurysmal SAH (aSAH). About 25% never reach medical attention (Diringer, 2009).

Cerebral vasospasm is an important cause of morbidity and death after SAH (Rowland et al., 2012), for those who survive to receive medical treatment. It is defined as clinical neurological symptoms of ischemia (confusion, decreased level of consciousness, focal neurological deficits), with narrowing of cerebral vessels, visualized by computed tomography angiography (CTA). Cerebral vasospasm occur in approximately one third of aSAH patients (Frontera et al., 2009), and the risk of vasospasm is related to the thickness and amount of blood in the subarachnoid space and/or the presence of intraventricular blood assessed on computed tomography (CT), the Fisher grade (Fisher et al., 1980; Jung et al., 2012). The risk of developing cerebral vasospasm is highest during dag 6–8 following ictus (Weir et al., 1978). SAH patients are clinically monitored with daily neurological examinations, but the means of diagnosing cerebral vasospasm varies. The techniques in use for diagnosing vasospasm are by means of clinical evaluation, transcranial doppler sonography (TCD), CTA, digital subtraction angiography (DSA), or by computed tomography perfusion (CTP) (Yoon et al., 2006; Washington and Zipfel, 2011; Kunze et al., 2012), although the most relevant technique is still not defined (Frontera et al., 2009).

A biomarker for detection of cerebral vasospasm in patients with SAH, could ideally allow for early detection to prevent delayed ischemic neurological deficits. Protein S100B is a calcium binding protein, predominant in nervous tissue, and mainly expressed in astroglial cells (Donato, 2001). It is also found in extracerebral tissues, such as long bones, fat, melanocytes, heart, and kidneys, though in lesser extent (Anderson et al., 2001; Unden et al., 2005). S100B is increased in serum and in cerebrospinal fluid (CSF) after brain injury, mainly as a result of the opening of the blood brain barrier (Marchi et al., 2003). In recent years, studies have shown that S100B is useful as a predictive marker for outcome after cerebral infarction (Herrmann and Ehrenreich, 2003; Ahmad et al., 2012), anoxic brain injury (Shinozaki et al., 2009), and SAH (Wiesmann et al., 1997; Stranjalis et al., 2007; Sanchez-Pena et al., 2008).

The aim of our study was to investigate the potential of S100B protein as a predictor of cerebral vasospasm in patients suffering from severe SAH.

Materials and Methods

We prospectively studied patients with SAH, admitted to Copenhagen University Hospital, neurointensive care unit (NICU) between September 2012 and January 2013. The inclusion criteria were: patients with SAH confirmed by CT, Fisher grade 3 and 4, age 18 years and above, admission and external ventricular drain (EVD) within 3 days of ictus, no other major injuries. Patients who had their EVD removed within the first 8 days after ictus were excluded from the study.

Glasgow Coma Scale (GCS) score (Teasdale and Jennett, 1974) and WFNS grading scale (Teasdale et al., 1988) was used to assess the neurological status on admission. Location and thickness of the hemorrhage on CT scan was determined by the Fisher grading scale (Fisher et al., 1980).


A total of five blood samples and five CSF samples were obtained from each patient. The day of ictus was defined as day 1. The first blood and CSF samples (Baseline sample) were obtained between day 1 and 3, depending on when the patient was transferred to the NICU and had received an EVD. The following four samples were obtained on day 5–8 following ictus. Each blood sample consisted of 4 ml of blood obtained in a SST-tube with separating gel without additives, and the CSF samples consisted of minimum 1 ml of CSF obtained from the EVD. About 4 ml of blood and 1 ml of CSF was taken as waste prior to sampling, as a precaution to contamination and dilution effect. Following collection all samples were centrifuged at 3500 rpm for 7 min at room temperature. The separated serum and CSF samples were stored at −80 °C, and thawed prior to analysis. Samples were analyzed with the method of electrochemiluminescence immunoassay, and the equipment used was Elecsys 2010, Modular Analytics E170, Roche Diagnostics (Mannheim, Germany). The lower detection limit was 0.005 and the upper limit 39 μg/L.


Daily neurological status was assessed to determine clinical signs of worsening with cerebral vasospasm as the primary cause. Cerebral vasospasm was confirmed by CTA.


Statistical analysis was performed in IBM SPSS Statistics ver. 19.0.0. Figures and tables were computed in Microsoft Excel 2007. Student t-test was performed for comparing mean S100B levels between patients with and without cerebral vasospasm. Significance level was set to 0.05.

Ethical considerations

The study and the collection of S100B in both serum and CSF had been approved by the local ethics committee.


A total of 18 patients with severe SAH were included, 16 had an aSAH, one had SAH due to a small AVM bleeding, and one due to dissection of the vertebral artery. Mean age was 60 years (range 42–84 years), there were 11 females and 7 males. The mean GCS score on admission was 8, the mean score of the WFNS grading scale was 3.5, and the mean Fisher grade was 3.6. Patients with aSAH were treated with endovascular coiling (81%) or surgical clipping (19%). The two patients without aSAH were treated conservatively.

The baseline samples were obtained on day 1 from one patient, on day 2 from four patients and on day 3 from 13 patients. Five patients developed cerebral vasospasm during the first week. None developed cerebral vasospasm later than on day 8. Three patients died, of which one developed cerebral vasospasm during the trial period. Two patients developed bacterial ventriculitis during the trial period.

When comparing patients who developed cerebral vasospasm with those who did not, there were no significant differences in GCS score at admission, Fisher grade or WFNS grade. Mean age was slightly, but not significantly, higher in patients that developed cerebral vasospasm (Table 1). The mean serum S100B level in patients who developed cerebral vasospasm compared to those who did not, was lower within the first 5 days after ictus. Following day 5, serum S100B levels in the group with cerebral vasospasm, was increased and exceeded the mean level of serum S100B in patients who did not developed vasospasm, though not statistically significant (Table 2). The mean CSF S100B levels in patients who developed cerebral vasospasm were lower compared to patients without vasospasm, but not statistically significant. The peak and mean body temperatures were generally high, but did not differ between those who developed vasospasm and those who did not.

Among the five patients who developed cerebral vasospasm, baseline samples of serum and CSF S100B were drawn on day 1 in one patient, at day 2 in one patient, and at day 3 in three. Two patients had increasing levels of serum S100B compared to the other three, which had an overall decreasing tendency and normal levels of serum S100B when vasospasm was diagnosed. Only one patient reached a peak level of serum S100B the day before vasospasm was confirmed (Figure 1, patient B), while the other patient reached peak S100B 1 day after angiographic confirmation of cerebral vasospasm and ongoing cerebral infarction (Figure 1, patient E). Both patients had a WFNS score of 5 and a GCS of 3 at admission, and both developed pneumonia during the trial period. The other three patients with cerebral vasospasm had slightly lower WFNS and slightly higher GCS scores at admission, and none had pneumonia or other infections diagnosed during the trial period.

Among patients who did not developed cerebral vasospasm, the baseline samples were drawn on day 2 in three patients and on day 3 in 13 patients. Two developed bacterial ventriculitis, with a sudden 10-fold increase in serum S100B levels. One reached peak level of serum S100B the day before developing ventriculitis, while peak levels for the other patient occurred on the same day as the infection was diagnosed. No such relation was observed for CSF S100B.


We studied a total of 18 SAH patients by measuring S100B in serum and CSF within the first 8 days following ictus. Five patients developed cerebral vasospasm, detected by neurological deterioration and confirmed with CTA. No significant differences for S100B levels were observed when comparing patients who developed cerebral vasospasm to patients who did not, and S100B failed predict the development of cerebral vasospasm.

Only two patients with cerebral vasospasm developed increased levels of serum S100B during the trial period. Both patients were in worse neurological condition (GCS 3, WFNS 5 at admission) compared to the other patients who developed cerebral vasospasm (Stranjalis et al., 2007). In addition, these two patients developed pneumonia during the trial period. Two patients in the group without cerebral vasospasm developed ventriculitis. High levels of serum S100B were found on the day before or on the same day as the clinical diagnosis of bacterial ventriculitis was set. The results indicate an association between increased serum S100B and intracerebral infections as shown in a previous study (Unden et al., 2004).

Measurements of S100B in our patients were done once daily with baseline sample obtained within the first 3 days of ictus and the rest of the four samples on days 5–8 following ictus. The baseline samples were obtained within the first 3 days of ictus, as cerebral vasospasm usually do not occur before day 4 following ictus. As the highest risk for developing vasospasm is between 6 and 8 days following the subarachnoid bleeding (Weir et al., 1978), the subsequent samples were drawn on day 5–8. None of the patients developed either clinical or angiographic vasospasm after day 8.

In two patients the bleeding source was not an aneurysm, but a small deep AVM in one patient, and a vertebral artery dissection in the other. The risk of developing cerebral vasospasm increases with increasing volume of subarachnoid blood visualized by CT (Fisher et al., 1980; Adams et al., 1987). Both of these patients had high amount of subarachnoid blood visualized on CT (Fisher grade 3 and 4), and thus high risk of developing cerebral vasospasm.

Currently, neurosurgical centers use daily assessment of neurological status, TCD sonography and CTA to determine the development of cerebral vasospasm. Most patients suffering from severe SAH, have already, prior to transport to the NICU, been sedated and intubated, making the assessment of the neurological status in these patients challenging. In our study, clinical suspicion of vasospasm in addition with CTA, rather than TCD, was used to diagnose cerebral vasospasm. CTA has been found to correlate well (overall agreement of 95%) with DSA (Yoon et al., 2006), which has been considered as the gold standard in detecting cerebral vasospasm. Furthermore, Kunze et al. (2012) have shown that the accuracy of neurological examination and CTP is higher in detecting cerebral vasospasm than TCD, and in a systematic review by Lysakowski and colleagues, they concluded that although TCD has a high specificity (0.99) and positive predictive value (0.97) for detecting vasospasm, this accounts only for the middle cerebral artery. For all the other arteries, there is no evidence for the usefulness of TCD as a diagnostic tool for vasospasm (Lysakowski et al., 2001).

Our study also show a tendency toward lower serum S100B levels during the first 5 days following SAH in patients who developed cerebral vasospasm compared to those who did not. These results were not statistically significant, thus not supporting useful value of serum S100B in predicting vasospasm. Similar results have been found by Oertel et al. (2006) who showed lower levels of serum S100B within the first 3 days after SAH in patients who developed cerebral vasospasm compared to those who did not. Cerebral vasospasm was determined by neurological deterioration and increasing flow velocity on TCD.

Identifying a specific biomarker for prediction of cerebral vasospasm in this group of patients is of high value, since earlier detection and hence earlier treatment of vasospasm could lower the morbidity and mortality in this group of patients. The statistical analysis of our end results are limited by the small number of cases enrolled in the study. We can, however, conclude that, although S100B is a promising prognostic biomarker of secondary brain damage and outcome in patients with SAH (Stranjalis et al., 2007; Sanchez-Pena et al., 2008), the potential of S100B as a predictor of cerebral vasospasm is very limited. This is in accordance with two previous studies (Moritz et al., 2010; Jung et al., 2013). The need of a marker in predicting cerebral vasospasm still remains, and other biomarkers such as myeloperoxidase (Lim et al., 2012), amino acids in addition to microdialysis (Jung et al., 2013), endothelin-1, interleukin-6, and indicators of thrombin activity might be of greater utility (Lad et al., 2012).

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The authors thank nurse Pia Breum Ferdinand, who assisted with recruitment and sampling.

Adams H. P. Jr.,Kassell N. F.,Torner J. C.,Haley E. C. Jr.. (Year: 1987). Predicting cerebral ischemia after aneurysmal subarachnoid hemorrhage: influences of clinical condition, CT results, and antifibrinolytic therapy. A report of the Cooperative Aneurysm Study. Neurology37, 1586–159110.1212/WNL.37.10.1586
Ahmad O.,Wardlaw J.,Whiteley W. N.. (Year: 2012). Correlation of levels of neuronal and glial markers with radiological measures of infarct volume in ischaemic stroke: a systematic review. Cerebrovasc. Dis.33, 47–5410.1159/00033281022133844
Anderson R. E.,Hansson L. O.,Nilsson O.,Dijlai-Merzoug R.,Settergren G.. (Year: 2001). High serum S100B levels for trauma patients without head injuries. Neurosurgery48, 1255–1258; discussion 1258–1260. 10.1097/00006123-200106000-0001211383727
de Rooij N. K.,Linn F. H.,van der Plas J. A.,Algra A.,Rinkel G. J.. (Year: 2007). Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. J. Neurol. Neurosurg. Psychiatr.78, 1365–137210.1136/jnnp.2007.11765517470467
Diringer M. N.. (Year: 2009). Management of aneurysmal subarachnoid hemorrhage. Crit. Care Med.37, 432–44010.1097/CCM.0b013e318195865a19114880
Donato R.. (Year: 2001). S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int. J. Biochem. Cell Biol.33, 637–66810.1016/S1357-2725(01)00046-211390274
Fisher C. M.,Kistler J. P.,Davis J. M.. (Year: 1980). Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery6, 1–910.1227/00006123-198001000-000017354892
Frontera J. A.,Fernandez A.,Schmidt J. M.,Claassen J.,Wartenberg K. E.,Badjatia N.,et al. (Year: 2009). Defining vasospasm after subarachnoid hemorrhage: what is the most clinically relevant definition?Stroke40, 1963–196810.1161/STROKEAHA.108.54470019359629
Herrmann M.,Ehrenreich H.. (Year: 2003). Brain derived proteins as markers of acute stroke: their relation to pathophysiology, outcome prediction and neuroprotective drug monitoring. Restor. Neurol. Neurosci.21, 177–19014530580
Jung C. S.,Lange B.,Zimmermann M.,Seifert V.. (Year: 2013). CSF and serum biomarkers focusing on cerebral vasospasm and ischemia after subarachnoid hemorrhage. Stroke Res. Treat.2013, 56030510.1155/2013/56030523509668
Jung S. W.,Lee C. Y.,Yim M. B.. (Year: 2012). The relationship between subarachnoid hemorrhage volume and development of cerebral vasospasm. J. Cerebrovasc. Endovasc. Neurosurg.14, 186–19110.7461/jcen.2012.14.3.18623210046
Kunze E.,Pham M.,Raslan F.,Stetter C.,Lee J. Y.,Solymosi L.,et al. (Year: 2012). Value of perfusion CT, transcranial doppler sonography, and neurological examination to detect delayed vasospasm after aneurysmal subarachnoid hemorrhage. Radiol. Res. Pract.2012, 23120610.1155/2012/23120623050146
Lad S. P.,Hegen H.,Gupta G.,Deisenhammer F.,Steinberg G. K.. (Year: 2012). Proteomic biomarker discovery in cerebrospinal fluid for cerebral vasospasm following subarachnoid hemorrhage. J. Stroke Cerebrovasc. Dis.21, 30–4110.1016/j.jstrokecerebrovasdis.2010.04.00420851633
Lim M.,Bower R. S.,Wang Y.,Sims L.,Bower M. R.,Camara-Quintana J.,et al. (Year: 2012). The predictive value of serum myeloperoxidase for vasospasm in patients with aneurysmal subarachnoid hemorrhage. Neurosurg. Rev.35, 413–419; discussion 419. 10.1007/s10143-012-0375-422370810
Lysakowski C.,Walder B.,Costanza M. C.,Tramer M. R.. (Year: 2001). Transcranial doppler versus angiography in patients with vasospasm due to a ruptured cerebral aneurysm: a systematic review. Stroke32, 2292–229810.1161/hs1001.09710811588316
Marchi N.,Rasmussen P.,Kapural M.,Fazio V.,Kight K.,Mayberg M. R.,et al. (Year: 2003). Peripheral markers of brain damage and blood-brain barrier dysfunction. Restor. Neurol. Neurosci.21, 109–12114530574
Moritz S.,Warnat J.,Bele S.,Graf B. M.,Woertgen C.. (Year: 2010). The prognostic value of NSE and S100B from serum and cerebrospinal fluid in patients with spontaneous subarachnoid hemorrhage. J. Neurosurg. Anesthesiol.22, 21–3110.1097/ANA.0b013e3181bdf50d20027011
Oertel M.,Schumacher U.,McArthur D. L.,Kastner S.,Boker D. K.. (Year: 2006). S-100B and NSE: markers of initial impact of subarachnoid haemorrhage and their relation to vasospasm and outcome. J. Clin. Neurosci.13, 834–84010.1016/j.jocn.2005.11.03016931022
Rowland M. J.,Hadjipavlou G.,Kelly M.,Westbrook J.,Pattinson K. T.. (Year: 2012). Delayed cerebral ischaemia after subarachnoid haemorrhage: looking beyond vasospasm. Br. J. Anaesth.109, 315–32910.1093/bja/aes26422879655
Sanchez-Pena P.,Pereira A. R.,Sourour N. A.,Biondi A.,Lejean L.,Colonne C.,et al. (Year: 2008). S100B as an additional prognostic marker in subarachnoid aneurysmal hemorrhage. Crit. Care Med.36, 2267–227310.1097/CCM.0b013e318180975018596638
Shinozaki K.,Oda S.,Sadahiro T.,Nakamura M.,Abe R.,Nakada T. A.,et al. (Year: 2009). Serum S-100B is superior to neuron-specific enolase as an early prognostic biomarker for neurological outcome following cardiopulmonary resuscitation. Resuscitation80, 870–87510.1016/j.resuscitation.2009.05.00519535196
Stranjalis G.,Korfias S.,Psachoulia C.,Kouyialis A.,Sakas D. E.,Mendelow A. D.. (Year: 2007). The prognostic value of serum S-100B protein in spontaneous subarachnoid haemorrhage. Acta Neurochir. (Wien)149, 231–237; discussion 237–238. 10.1007/s00701-006-1106-917242846
Teasdale G.,Jennett B.. (Year: 1974). Assessment of coma and impaired consciousness. A practical scale. Lancet2, 81–8410.1016/S0140-6736(74)91639-0
Teasdale G. M.,Drake C. G.,Hunt W.,Kassell N.,Sano K.,Pertuiset B.,et al. (Year: 1988). A universal subarachnoid hemorrhage scale: report of a committee of the World Federation of Neurosurgical Societies. J. Neurol. Neurosurg. Psychiatr.51, 145710.1136/jnnp.51.11.14573236024
Unden J.,Bellner J.,Eneroth M.,Alling C.,Ingebrigtsen T.,Romner B.. (Year: 2005). Raised serum S100B levels after acute bone fractures without cerebral injury. J. Trauma58, 59–6110.1097/01.TA.0000130613.35877.7515674151
Unden J.,Christensson B.,Bellner J.,Alling C.,Romner B.. (Year: 2004). Serum S100B levels in patients with cerebral and extracerebral infectious disease. Scand. J. Infect. Dis.36, 10–1310.1080/0036554031001729415000552
van Gijn J.,Rinkel G. J.. (Year: 2001). Subarachnoid haemorrhage: diagnosis, causes and management. Brain124, 249–27810.1093/brain/124.2.24911157554
Washington C. W.,Zipfel G. J.. (Year: 2011). Detection and monitoring of vasospasm and delayed cerebral ischemia: a review and assessment of the literature. Neurocrit. Care15, 312–31710.1007/s12028-011-9594-821748499
Weir B.,Grace M.,Hansen J.,Rothberg C.. (Year: 1978). Time course of vasospasm in man. J. Neurosurg.48, 173–17810.3171/jns.1978.48.2.0173624965
Wiesmann M.,Missler U.,Hagenstrom H.,Gottmann D.. (Year: 1997). S-100 protein plasma levels after aneurysmal subarachnoid haemorrhage. Acta Neurochir (Wien).139, 1155–116010.1007/BF014109769479422
Yoon D. Y.,Choi C. S.,Kim K. H.,Cho B. M.. (Year: 2006). Multidetector-row CT angiography of cerebral vasospasm after aneurysmal subarachnoid hemorrhage: comparison of volume-rendered images and digital subtraction angiography. AJNR Am. J. Neuroradiol.27, 370–37716484413


[Figure ID: F1]
Figure 1 

Serum S100B levels for the five patients with cerebral vasospasm. Day 1 = day of ictus. Baseline sampling was made between day 1 and 3. The dotted lines are extrapolations from baseline sample to the second sample drawn on day 5. The day on which cerebral vasospasm was confirmed is indicated for each patient.

[TableWrap ID: T1] Table 1 

Characteristics of patients with cerebral vasospasm compared to patients without.

Cerebral vasospasm n = 5 No cerebral vasospasm n = 13
Gender (M:F) 2:3 5:8
Mean age (years) 67 58
Mean GCS at admission 8 9
Mean WFNS grading score at admission 3.6 3.5
Mean Fisher grading score 3.6 3.5
Mean body temperature (°C) 38.0 38.0
Intracranial infection 0 2
Death 1 2
Sample collection (n)
 Day 1 1 0
 Day 2 1 3
 Day 3 3 10
Days 5–8 5 13

GCS, glasgow coma scale; WFNS, World federation of neurological societies grading scale.

[TableWrap ID: T2] Table 2 

Mean serum and CSF S100B levels in patients with cerebral vasospasm compared to patients without*.

Samples Mean serum S100B (μg/L)
Mean CSF S100B (μg/L)
Cerebral vasospasm N = 5 No cerebral vasospasm N = 13 Cerebral vasospasm N = 5 No cerebral vasospasm N = 13
Baseline 0.10 0.19 23.5 29.6
Day 5 0.15 0.37 13.8 21.8
Day 6 0.21 0.15 10.1 16.3
Day 7 0.27 0.11 12.7 15.7
Day 8 0.24 0.25 12.0 12.3

tfn1*There are no statistical differences between the two groups (vasospasm vs. no vasospasm).

Article Categories:
  • Neuroscience
    • Original Research

Keywords: protein S100B, subarachnoid hemorrhage, cerebral vasospasm, CT angiography, cerebrospinal fluid, serum.

Previous Document:  Perceptual load vs. dilution: the roles of attentional focus, stimulus category, and target predicta...
Next Document:  Parkinson's disease rigidity: relation to brain connectivity and motor performance.